Trials / Terminated
TerminatedNCT00771316
Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)
A Phase 3, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK0826 and Meropenem in Patients With Complicated Urinary Tract Infection
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate that MK0826 is comparable to Meropenem in the treatment of complicated Urinary Tract Infections (UTIs) in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0826 (ertapenem) | A single dose of 1.0g IV infused over a 30 minute interval at hour 0 |
| DRUG | Comparator: meropenem | 500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2008-10-13
- Last updated
- 2017-03-21
- Results posted
- 2010-07-09
Source: ClinicalTrials.gov record NCT00771316. Inclusion in this directory is not an endorsement.